AU5649290A - Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccine - Google Patents
Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccineInfo
- Publication number
- AU5649290A AU5649290A AU56492/90A AU5649290A AU5649290A AU 5649290 A AU5649290 A AU 5649290A AU 56492/90 A AU56492/90 A AU 56492/90A AU 5649290 A AU5649290 A AU 5649290A AU 5649290 A AU5649290 A AU 5649290A
- Authority
- AU
- Australia
- Prior art keywords
- cell
- peptide
- product
- boc
- malarial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 77
- 239000000412 dendrimer Substances 0.000 title claims description 39
- 229920000736 dendritic polymer Polymers 0.000 title claims description 39
- 229960005486 vaccine Drugs 0.000 title claims description 25
- 239000000427 antigen Substances 0.000 title description 48
- 102000036639 antigens Human genes 0.000 title description 47
- 108091007433 antigens Proteins 0.000 title description 47
- 230000000078 anti-malarial effect Effects 0.000 title description 2
- 239000003430 antimalarial agent Substances 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 25
- 125000000524 functional group Chemical group 0.000 claims description 19
- 201000004792 malaria Diseases 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 241000223960 Plasmodium falciparum Species 0.000 claims description 12
- 230000000890 antigenic effect Effects 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 241000224017 Plasmodium berghei Species 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 6
- 241000223801 Plasmodium knowlesi Species 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 claims description 2
- 101710117490 Circumsporozoite protein Proteins 0.000 claims description 2
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 claims description 2
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 claims description 2
- 241000223821 Plasmodium malariae Species 0.000 claims description 2
- 206010035501 Plasmodium malariae infection Diseases 0.000 claims description 2
- 241001505293 Plasmodium ovale Species 0.000 claims description 2
- 206010035502 Plasmodium ovale infection Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- 229920005989 resin Polymers 0.000 description 36
- 239000011347 resin Substances 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 35
- 238000009448 modified atmosphere packaging Methods 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 28
- 239000000047 product Substances 0.000 description 24
- 229920000642 polymer Polymers 0.000 description 22
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 17
- 230000008878 coupling Effects 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 17
- 210000003046 sporozoite Anatomy 0.000 description 17
- 239000004472 Lysine Substances 0.000 description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
- 125000003277 amino group Chemical group 0.000 description 16
- 235000018977 lysine Nutrition 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- -1 acrylic ester Chemical class 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- 108010016626 Dipeptides Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 235000019837 monoammonium phosphate Nutrition 0.000 description 6
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 241000223810 Plasmodium vivax Species 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 229940126577 synthetic vaccine Drugs 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 2
- 208000009182 Parasitemia Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BMJRTKDVFXYEFS-XIFFEERXSA-N (2s)-2,6-bis(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CCCCNC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 BMJRTKDVFXYEFS-XIFFEERXSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- SNZIFNXFAFKRKT-NSHDSACASA-N (2s)-2-azaniumyl-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoate Chemical compound CC(C)(C)OC1=CC=C(C[C@H]([NH3+])C([O-])=O)C=C1 SNZIFNXFAFKRKT-NSHDSACASA-N 0.000 description 1
- JYEVQYFWINBXJU-QFIPXVFZSA-N (2s)-6-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JYEVQYFWINBXJU-QFIPXVFZSA-N 0.000 description 1
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LXUNZSDDXMPKLP-UHFFFAOYSA-N 2-Methylbenzenethiol Chemical compound CC1=CC=CC=C1S LXUNZSDDXMPKLP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-REOHCLBHSA-N 3-amino-L-alanine Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- HJEINPVZRDJRBY-UHFFFAOYSA-N Disul Chemical compound OS(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl HJEINPVZRDJRBY-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- VGALFAWDSNRXJK-VIFPVBQESA-N L-aspartic acid beta-benzyl ester Chemical compound OC(=O)[C@@H](N)CC(=O)OCC1=CC=CC=C1 VGALFAWDSNRXJK-VIFPVBQESA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 101100270435 Mus musculus Arhgef12 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000224028 Plasmodium cynomolgi Species 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004192 high performance gel permeation chromatography Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000037369 susceptibility to malaria Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
"DENDRITIC POLYMER OF MULTIPLE ANTIGEN PEPTIDE SYSTEM USEF AS ANTI-MALARIAL VACCINE"
Vaccines often comprise an antigen on a natural carrie such as a protein, a carbohydrate, a lipid or a liposome. Suc vaccines are useful and have been employed for many years. There are however a number of art recognized problems wit them. Several of these problems are related to the carrier. Since the carriers are isolated from natural sources, they ar often not of uniform quality. Additionally, despite expensiv and arduous purification efforts, it is difficult, and ofte impossible, to provide products completely free of natura contaminants. Such contaminants may themselves be antigenic. They cause the undesirable side reactions often associated wit the use of vaccines, particularly fevers and tissue swelling Additionally, the concentration of antigen may vary from on batch to another because the amounts of antigen which reac with the carrier or are absorbed on its surface are no uniform. This problem has markedly increased the difficultie of preparing suitable vaccines for protection against malaria.
Malaria is a particularly important target for syn thetic vaccines, since it affects 200 million people worldwid and no immunoprophylaxis has yet been developed. It is know that protective immunity against rodent, simian and huma malaria sporozoites can be induced by immunization wit irradiated sporozoites. The major protein of the sporozoite i the circumsporozoite (CS) protein, and antibodies directe against the CS protein are known to neutralize the infectivit of parasites and inhibit their entry into the hepatocytes
Thus, the CS protein has become an important target for the development of synthetic vaccines against the sporozoite stage of malaria. The im unodominant B-cell epitopes of the CS protein is contained within the repeating domain of the CS protein, a feature common to CS proteins of all malaria species. Mice immunized with a synthetic peptide, attached to tetanus toxoid as a protein carrier of this B-cell epitope, have been found to develop high antibody titers and resistance to challenge with 10^ sporozoites. However, vaccination attempts in humans, using a similar approach, have failed to induce good antibody titers.
Recently, several T-helper cell epitopes of the CS protein of P. berσhei (a rodent malaria) have also been identified (see Romero et al., Eur. J. Immunol. 1.8:1951, 1988). The identification of the B and T helper cell epitopes of the CS protein of P. berσhei has now made it possible to incor¬ porate these epitopes into one molecule in a specific and unambiguous manner using the MAP approach in which the epitopes are attached to a defined dendritic polymer, using the procedure developed by Tarn and his coworkers as described in J. Biol. Chem. 263, 1719 (1988). In addition, T-cell epitopes of other malarial species have been identified: See, e.g. , Sinigaglia, F. et al, Nature 336:778, 1988 (P. falciparum) ; Crisanti, A. et al., Science, 240:1324, 1988 (P. falciparum, blood stage); Kumar, S. et al.. Nature 334:258, 1988 (P. falciparum sporozoites) etc: Good, M.S. et al, Science 23_5:1059-1062, 1987; Good, M.S., et al, Proc. Nat'l. Acad. Sci. 85.:1199-1203, 1988; Sinigaglia, F. , et al. , Eur. J. Immunol. 18:633-636, 1988; and Guttinger, M. , et al., EMBO J. 2:2555- 2557, 1988.
Dendritic polymers are a new class of polymers. They are characterized by higher concentrations of functional groups per unit of molecular volume than ordinary polymers. General¬ ly, they are based upon two or more identical branches origin- ating from a core molecule having at least two functional groups. Such polymers have been described by Denkewalter et al. in U.S. Patent No. 4,289,872 and by Tomalia et al. in
several U.S. Patents including Nos. 4,599,400 and 4,507,466. Other polymers of the class have been described by Erickson in U.S. Patent 4,515,920. The polymers are often referred to as dendritic polymers because their structure may be symbolized as a tree with a core trunk and several branches. Unlike a tree, however, the branches in dendritic polymers are all substan¬ tially identical.
The products of this invention are based on such dendritic systems in which antigens are covalently bound to the branches which radiate from the core molecule. The system has been termed the multiple antigen peptide system and is some¬ times referred to herein as MAPS. As will be apparent from the discussion hereinafter, some of the carrier or core molecules used to form the products of the invention are of a molecular weight such that they might not usually be regarded as poly¬ mers. However, since their basic structure is similar to dendritic polymers, it is convenient to describe them as such. Therefore, the term "dendritic polymer" will be sometimes used herein to define the polymeric substrates of the products of the invention. The term includes carrier molecules which are sufficiently large to be regarded as polymers as well as those which may contain as few as three monomers.
It has now been discovered that dendritic polymers can function usefully as carriers for a wide variety of antigens. This invention will be better understood from a brief discussion of the structure of dendritic polymers.
Dendritic polymers are built upon a core molecule which is at lease difunctional. Each of the functional groups on the core molecule form at least two branches, the principal units of which are also at least difunctional. Each difunctional unit in a branch provides a base for added growth.
The system can be better visualized by reference t specific molecules. If, for example, lysine with two amin groups is joined in a peptide bond through its carboxyl grou to the amino group of alanine or glycine which may in turn be bound to a resin, the resulting molecule will have two fre amino groups. This dipeptide may be regarded as the firs
generation. It may be joined to two additional lysine mole¬ cules by the formation of peptide bonds to produce a second generation molecule with four free amino groups. The process can be repeated to form third, fourth or even higher genera- tions of products. With each generation the number of free amino groups increases geometrically and can be represented by 2n, where n is the number of the generation.
Although none of these compounds are of particularly high molecular weight, it is convenient to refer to them as dendritic polymers.
Fig. 1 shows a three generation dendritic polymer core molecule based on lysine in which each of the eight available amino groups are joined to a peptide antigen through a glycine linker molecule. The same types of reactions can be carried out with aspartic or glutamic acid, both of which have two carboxyl groups and one amino group to produce polyaspartic or poly- glutamic acids with 2n free carboxyl groups.
The necessary chemistry for performing these types of synthesis "is known and available. With amino acids the chemistry for blocking functional groups which should not react and them removing the blocking groups when it is desired that the functional groups should react has been described in detail in numerous patents and articles in the technical literature. The dendritic polymers can be produced on a resin as in the well-known Merrifield synthesis and then removed from the polymer.
Tomalia utilized ammonia or ethylenediamine as the core molecule. In this procedure, the core molecule is reacted with an aerylate ester by Michael addition and the ester groups removed by hydrolysis. The resulting first generation mole¬ cules contain three free carboxyl groups in the case of ammonia and four free carboxyl groups when ethylenediamine is employed. Tommalia extends the dendritic polymer with ethylenediamine followed by another acrylic ester monomer, and repeats the sequence until the desired molecular weight is attained. It will, however, be readily apparent to one skilled in the art,
that each branch of the dendritic polymer can be lengthened by any of a number of selected procedures. For example, each branch can be extended by multiple reactions with lysine molecules. Erickson utilized the classic Merrifield technique in which a polypeptide of substantially any desired molecula weight is grown from a solid resin support. As the technique is utilized for the preparation of dendritic polymers, the linking molecule which joins the polymer to the resin support is trifunctional. One of the functional groups is involved i the linkage to the resin, the other two functional groups serv as the starting point for the growth of the polymer. Th polymer is removed from the resin when the desired molecula weight has been obtained. One standard cleavage procedure i treatment with liquid hydrogen fluoride at 0°C for one hour.
Another, and more satisfactory procedure, is to utilize complex of hydrogen fluoride and dimethylsulfide (HF:DMF) a described by Tarn et al. in J. Am. Soc. (1983) 105: 6442. Thi procedure greatly minimizes side reactions and loss of peptide. Denkewalter, in one example of his process, utilize lysine as the core molecule. The amino groups of the cor molecule are blocked by conversion to urethane groups. Th carboxyl group is blocked by reaction with benzhydrylamine
Hydrolysis of the urethane groups generates a benzhydrylamid of lysine with two free amino groups which serve as th starting points for the growth of the dendritic polymer.
This brief outline of three of the available procedure for producing dendritic polymers should be adequate to teac those skilled in the art the basis principles of the curren technology. They will also teach the skilled artisan th salient features of the polymers, one of the most important o which is that the polymers provide a large number of availabl functional groups in a small molecular volume. The result i that a high concentration of antigens in a small volume can b achieved by joining the antigen to those available functiona groups. Moreover, the resulting molecular product contains high proportion of antigen on a relatively small carrier. Thi
is in contrast to conventional products used as a basis for vaccines. These conventional products often are composed of a small amount of antigen on a large amount of carrier.
Other important features of the dendritic polymer as an antigen carrier are that the exact structure is known; there are no contaminants which may be themselves antigenic, produce tissue irritation or other undesirable reactions; the exact concentration of the antigen is known; the antigen is symmetri¬ cally distributed on the carrier; and the carrier can be utilized as a base for more than one antigen so that ulti- valent vaccines can be produced. The principal advantage of the MAPS technique as the basis for malarial vaccines of this invention is that unlike previous systems using natural carriers such as keyhole limpet hemocyanin, tetanus toxoid and bovine serum albumin, the carriers of this invention are fully defined chemical entities on which the antigens are dispersed in known concentrations. Additionally the antigen comprises a large part of the molecule not a relatively small and undefined proportion of the molecule as in the case of natural carriers. For the vaccines of this invention, it is preferred that the core molecule be a naturally occurring amino acid such as lysine so that it can be dealt with by the body following the usual metabolic pathways. However, as will be explained more fully hereinafter, amino acids which are not naturally occurring, '"even those which are not alpha-amino acids can be employed. The acids, or any other asymmetric molecules used in building the core molecule can be in either the D or L form.
Although the dendritic polymers have been principally described hereinabove as polyamide polymers, it will be readily apparent that the carriers of this invention are not limited to dendritic polyamides. Any of a wide variety of molecules having at least two available functional groups can serve as core molecules. Propylene glycol, for example, can serve as the basis for a polyester dendritic polymer. Succinic acid with selected glycols or amines can serve as a core molecule to generate polyesters or polyamides. Diisocyanates can be used to generate polyurethanes. The important point is that the
core molecule has at least two available functional groups fro which identical branches can be generated by sequentia scaffolding-type reactions with additional molecules als having at least two available functional or anchoring groups o each branch. In the most simple case in which the cor molecule has two available functional groups and each succeed ing generation has two available functional groups, the numbe of anchoring sites to which malarial-origin T-cell and B-cel antigens employed in this invention can be anchored is ex pressed by (2)n where n is the number of the generation.
For a more complete discussion of the chemistry o dendritic polymers attention is directed to Ta alia et al.
Polymer Journal 17 (1), 117 (1985), Akaroni et al, Mar comolecules 15, 1093 (1982), and the following United State Patents:
4,289,872 4,558,120
4,376,861 4,568,737
4,507,466 4,587,329
4,515,920 4,599,400 4,517,122 4,600,535
All cited patents, patent applications and reference are incorporated by reference in their entirety.
THE INVENTION This invention in its presently preferred embodiment provides a multiple antigen peptide system comprising dendritic polymer base with a plurality of anchoring site covalently bound to antigenic T-cell and B-cell epitopes o malarial proteins such as the CS protein such that the result ing construct bears both T and B epitopic peptides. T polymers comprise a central core molecule having at least t functional groups to which molecular branches having termin functional groups are covalently bound. The terminal functio al groups on the branches are covalently bonded to the epitop peptides. The antigenic molecules are principally describ herein as peptide antigens, but they are not limited to pepti antigens or even to antigens. Thus, peptides that are n antigenic by themselves may be rendered antigenic when bound
the core molecule.
The selected antigen may be separately synthesized (by synthetic methods, including but not limited to recombinant DNA techniques, as is now well-known in the art) or otherwise obtained and joined to the carrier. Preferably, the antigen may be synthesized on the carrier by extending each branch of the polymer utilizing known peptide synthesis techniques.
Fig. 1 shows the structure of a dendritic polymer which may be employed in the practice of this invention. As will be seen, it is a three generation dendritic polylysine product. It may be produced by a conventional solid phase techniques by generating the polymer on a Pair, or a Pop resin. See Mitchell et al., J. Org. Chem. (1978) ϋ, 2845 and Tarn et al., J. Am. Chem. Soc, (1980) 102 6117. The polymer is then cleaved from the resin using, preferably HF:DMS. The dendritic polylysine, as shown, was built from a glycine linker originally joined through a benzyl linker to the resin. Other linkers such as alanine can be employed. Of course, the linker can be omitted, or a plurality of linker molecules can be utilized. Fig. 1 shows a dendritic polymer each molecule of which carries eight peptides some of which represent T-cell epitopic peptides and others B-cell epitopic peptides of a Plasmodium species responsible for malaria, e.g., Plasmodium berqhei, Plasmodium falciparum or Plasmodium vivax. P. yoelii. P. malariae, P. ovale, P. cynomolgi, P. knowlesi: etc. joined directly to each of the available functional groups on each terminal lysine moiety. It is preferable that the B- and T- epitopes o& the polymer are of the same malarial species. The the present invention is not limited to polymers bearing only one T- and B-epitope combination from a single species. For example, MAPS bearing simultaneously T- and B-epitopes from P.vivax CS protein and T- and B-epitopes from P.falciparum CS protein are within the scope of the invention. In addition, the ability of a peptide to function as a T-helper epitope is not necessarily dependent upon the copresence of a B-cell epitope from the same malarial species. Hence, cross-species combinations of T-helper and B-cell epitopic peptides are also
contemplated. When the selected epitopic structures ar relatively short, e.g. 6 to 14 residues, it has been observe that it is best to extend the polylysine by a linker such as simple tri- or tetrapeptide of glycine, alanine or beta alanine. However, for antigenic peptides with more than 1 residues, the linker is normally unnecessary.
This invention has been described for convenience principally as applied to products built on lysine as the cor molecule. In fact lysine and lysine like molecules such a ornithine, nor-lysine and beta-amino alanine are preferre molecules for building the products of this invention becaus they are relatively easy to obtain, they are easy to work wit and they afford good yields.
Such molecules can be represented by the genera formula:
(CH2)y NH2 H2N - (CH2)X - C - (CH2)2 COOH H wherein x, y and z are integers from 0 to 10, preferably 0 to provided that at least one of them is 1 and the amino group cannot be attached to the same carbon atom. In the mos preferred molecules the total of x, y and z is from 2 to 6 an the amino groups are separated by at least two methylen groups. Other preferred core molecules include ethylene diamin and like molecules with longer chains such as propylene diamin and butylene diamine. Such molecules may be represented by th general formula:
H N CH2 (CH2)n - CH2 NH2 wherein n is an integer from 0 to 10, preferably 0 to 3.
Of course, ammonia can also be employed as the cor molecule.
The development of synthetic vaccines against a larg number of diseases has recently been greatly accelerate because of the recognition that a vaccine need not be based o a native protein, but may be based on a low molecular weigh segment of the native protein. These segments, normally calle
immunogenic determinants or epitopes are capable of stimulating the production of antibodies which will protect against infection by sporozoites bearing the native protein antigen and in turn introduced in the mammalian host by the bite of a mosquito vector.
This invention is concerned with malarial-origin T- and
B-cell epitopic peptides such as those described by Romero, et al., Loc. cit. which is incorporated herein by reference. By way of nonlimiting example, some of the P. berghei T-cell epitopic peptides are:
Designation YNRNTVNRLLAD 1
59 69
NEKIERNNKLKQP N 80 92
NDDSYIPSAEKI 3
249 260
KQIRDSITEEWS B-4
265 ' 276 GSGIRVRKRKGSNK 5
283 296
SSIFNIVSNSLG 6
317 328
NEKIERNNKLKQPDPPPPNPNDPPPPNPND N-t-17.1 KQIRDSITEEWSDPPPPNPNDPPPPNPND B-4+17.1
The last two antigens N+17.1 and B-4+17.1 represent a combination of T-cell epitopes N or B-4 with a B-cell epitope 17.1. The epitope 17.1 and its preparation are described in Zavala et al., J. Exp. Med. , 166:1591, 1987, which is incor- porated by reference. It should be noted that in the case of circumsporozoite protein, the B-cell epitope (which happens to be the imraunodominant epitope) is repetitive in nature, e.g., (DPPPPNPN)χ for P. berghei: (DRAAGQPAG)χ or (DRADGQPAG)χ or combinations of the two for P. vivax: (NANP)X for P. fal- ciparum, (QAQGDGANAGQP)χ for P. knowlesi. etc. wherein x is at least 2 for at least some malarial species. Repeats of cyclic permutations of these minimum repeating units will also yield
B-cell epitopic peptides, e.g. (PNAN) .
Some of the antigenic peptides which are currently available either commercially or by known synthetic or isolation techniques are listed in Table 1, below. The table lists the peptides which are segments of proteins associated with the disease or pathogen identified in the second column. The references identify the publications which describe the peptides and how to obtain them. The conventional abbreviations are used for the amino acids.
TABLE 1
PEPTIDE SEQUENCES SUITABLE FOR DEVELOPMENT OF VACCINES USING MAPS
Peptide Pathogen/Disease (protein) Ref
A. H-(Asn-Ala-Asn-Pro) -CH n>3 Malaria, CS protein of P. falciparum 1
B. H-(Gly-Asp-Arg-Ala-Asp-Gly Malaria, CS protein of
Gin-Pro-Ala)n-OH n>2 P. vivax 2
C. Glu-Gln-Asn-Val-Glu-His- Malaria, Pf 155 of
Asp-Ala P. falciparum 3
D. Asn-Ala-Glu-Asn-Lys-Glu-Glu- Malaria, Marozoite surface
Leu-Thr-Ser-Ser-Asp-Pro-Glu- protein of P. falciparum 4 Gly-Gln-Ile-Mat
E. Asn-Ala-Asn-Pro-Asn-Val- Malaria, CS protein of 5 Asp-Pro-Asn-Ala-Asn-Pro P. falciparum
1. Zavala, et al. Science 228:1436, 1985
2. McCutchan, et al. Science 230:1381, 1985; Arnot, D.E., et al, Science, 230:815 (1985)
3. Udomsangpetch, et al, Science 231:57, 1986
4. Ravetch, et al, Science 227:1593, 1984 5. Nardin, E.H. et al, Science 246:1603, 1989
In addition, malarial T-helper cell epitopic peptides can be identified, as described above in the references of Sinigaglia et al etc. Briefly, once the amino acid sequence of a malarial protein is lcnown, peptides corresponding to fragments of the protein can be synthesized and injected in mammals. T- cells
SUBSTITUTESHEET
can then be harvested from blood samples of the immunized mammals and incubated in vitro in the presence of the peptide used for immunization. Such peptide are considered T-helper cell epitopic peptides if the T-cells proliferate during such incubation in the presence of such a peptide. To demonstrate whether these T-cell peptides are T-helper peptides, they are tested for elicitation of antibodies to a B-cell epitope by covalently linking the T- cell and the B-cell epitopic peptide and using the thus formed conjugate for immunization. In the foregoing description the letters have the same meaning as is employed by those skilled in the peptide arts. These are:
A-alanine M-methionine
C-cystine N-asparagine D-aspartic acid P-proline
E-glutamic acid Q-glutamine
F-phenylalanine R-arginine
G-glycine S-serine
H-histidine T-threonine I-isoleucine V-valine
K-lysine W-tryptophan
L-leucine Y-tyrosine
A particular advantage of this invention is that the dendritic polymer can serve as a carrier for two or more dif- ferent malarial antigens. This is particularly useful for producing multivalent vaccines (i.e. vaccines directed against more than one malarial species) and/or for producing vaccines against different stages of the malaria parasite. Vaccines produced from antigenic products of the invention in which both T-cell antigens and B-cell antigens associated with malaria are joined to the dendritic polymer in any of the various configura¬ tions illustrated in a non-limiting fashion in Figure 2 are especially useful because they are capable of generating extreme¬ ly high antibody titers. It has been discovered that when the T- and B-cell epitopes of this invention are covalently bound to MAP sub¬ strates, the resulting products will elicit levels of antibody
response which are 10 to 100 fold greater than those obtained in the past with recombinant CS protein or irradiated sporozoites. It has been further observed that, in mice, the B-T monomeric di- epitope not supported on a MAP substrate, or a mixture of B- epitope MAP and T-epitope MAP produced very low antibody response and no protection. The presently most preferred embodiment of the present invention is one where both a T and a B epitopic peptide are linked in tandem on the same functional group of the dendritic polymer substrate. The specifically selected B- and T-epitopes of this invention can be placed on the MAP substrate in a variety of different arrangements as shown in Fig. 2. The figure shows alternate arrangement for the B-epitope (open blocks) and the T- epitope (solid blocks) which for P. berghei include PPPPNPDPPPPNPND and KQIRDSITEEWS, respectively.
In Figure 2, T-(4) and B-(4) are monomeric maps wit four branches but only one epitope (again the immunodominant B- epitope for the CS protein comprises at least two occurrences of the repetitive unit). T-(8) and B-(8) are similar, but with 8 branches. In T(8)B and B(8)-T, there are 8 T or B epitopes o the branches of the dendritic polymer and one B-epitope or T epitope on the root of the polymer. BT-(4), TB-(4), BT-(8) an TB-(8) illustrate presently preferred products of the inventio in which the epitopes are arranged in tandem. Naturally, it will be apparent to those skilled in th art that many combinations and numbers of malarial T- and B epitopes are contemplated herein and are fully within the scop of the present invention.
It is also possible to produce products of the inven tion in which the B- and T-epitopes are arranged alternatively o the branches, i.e., one branch has only B-epitopes, the othe only T-epitopes. For instance, in Fig. 2, T/B(8) represents a eight branch dendritic polymer base with alternating T and malaria antigens, within the scope of the invention; T/B(4) i similar except that the polymer base has only four branches.
This is accomplished utilizing the orthogonal protec tion method by employing a dendritic polymer based on a diamin
compound such as lysine in which the amino groups are blocked with different amino blocking groups, one of which is stable to acid hydrolysis, the other of which is stable to alkaline hydrolysis. (See, for example, the schematic representation of Fig. 2, E and F) .
Fluorenylmethyloxycarbonyl (Fmoc) is a base labile protecting group and is completely stable to acidic deprotection. The t-butoxycarbonyl blocking group (Boc) is stable under mildly acidic conditions such as 50% trifluoroacetic acid. By choosing Boc-l s (Boc)-OH, Boc-lys (Fmoc)-OH, Fmoc-lys Boc)-0H or Fmoc-lys (Fmoc)-OH, it is possible to place one set of antigens on the alpha amino group of lysine and another on the omega amino group. Those skilled in the art of peptide synthesis can readily devise methods of achieving the same types of products using diverse blocking groups and other dendritic polymers.
It will be apparent to those skilled in the art that many variations of the structures shown and discussed herein are possible. For example, the dendritic polymer may have a struc¬ ture in which segments are joined through a disulfide bridge. Such structures can be readily xormed from dendritic polymers in which the root contains a protected cystine which is oxidized by a mild oxidizing agent such as molecular iodine.
As another example, referring to Fig. 1, the glycine at the root of the dendritic polymer, i.e., the free glycine could be joined to, or replaced with, a T- or B-malarial peptide antigen which may be the same or different from the other peptide antigens on the branches of the dendritic polymer molecule. The T- and B-peptide antigens themselves may serve as the residue to which other lysine or similar molecules may be attached to provide additional branches to which still additional peptide antigens, antibiotics or non-peptide antigens may be attached.
The products of this invention can be employed to produce vaccines useful to protect against malarial infections of mammals including humans using any of the procedures known to those skilled in the art. The products can, for example, be suspended in a pharmaceutically acceptable medium or diluent, such as inert oil, suitably a vegetable oil such as sesame,
peanut or olive oil. Alternatively, they can be suspended in an aqueous isotonic buffer solution at a pH of about 5.6 to 7.4. Typically, such solutions will be made isotonic with sodium chloride and buffered with sodium citrate-citric acid or with phosphate. The solutions may be thickened with a thickening agent such as methyl cellulose.
Vaccines may also be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder or an alkaryl polyether alcohol, sulfonate or sulfate such as a Triton.
Stabilizers such as sorbitol or hydrolyzed gelatin may also be adαed to any of the above described compositions. It is not unusual to incorporate an antibiotic such as neomycin or other anti-infective agents to prevent infection.
Because the products of this invention provide such high antibody titers, in many instances they will be employed without carriers or adjuvants. However, if an adjuvant is employed it may be selected from any of those normally employed to stimulate the immunogenic system of mammals. These include, for example, Freund's adjuvant (complete or incomplete). Adjuvant 65 (containing peanut oil, mannide monooleate and aluminum monostearate), and mineral gels such as aluminum phosphate or alum; killed Bordetella, tetanus toxoid, diphtheria toxoid, muramyl dipeptide, aluminum hydroxide, saponin, etc., but as stated above, such adjuvants or carriers are not necessary when the polymeric substrate of the present invention is used. Freund's adjuvant is no longer used in vaccine formulations for humans or for food animals because it contains nonmetabolizable mineral oil and is a potential carcinogen. It can be used in vaccines for non-food animals. Mineral gels are widely used in commercial veterinary vaccines.
The vaccines of the invention may be defined as comprising a pharmaceutically acceptable carrier, of the general nature described above, together with an amount of an antigenic product of the invention , i.e., a selected T- or B-cell epitope which is sufficient to produce an immunological response, i.e., a
protective antibody response in a mammal. An effective amount may be very small. It will, as is known, vary with the antigen. The quantity which constitutes an effective amount may vary depending on whether the vaccine is intended as a first treatment or as a booster treatment.
The amount of MAP will vary depending upon the specific immunogen, the response it elicits in various subjects, and the presence or absence of heterologous carrier or adjuvant. Generally, amounts within the range from about 1 to about 1,000 micrograms of MAP are contemplated. Optimal amounts can be ascertained by routine experimentation involving measurement of antibody titers and other parameters of mammalian immune res¬ ponse, as is well-known in the art. Repeat immunizations are preferred. It may be convenient to provide the products of this invention as lyophilized or freeze dried powders ready to be reconstituted with a pharmaceutically acceptable carrier just prior to use.
Additional information on vaccine preparations and protocols is well-known. See, for example, European Application No. A 191,748 of SmithKline Beck an published on August 20, 1986; European Patent Application No. Aj 192,626 of SmithKline Beckman et al. published August 27, 1986; U.S. Patent Nos. 4,693,994; 4,707,357; 4,735,799; and 4,767,622. All cited patents, patent applications and literature are incorporated by reference in their entirety.
Thus, this invention also provides a method of provid¬ ing immunity in a mammal against infection by a malarial organism which comprises administering to the mammal an immunogenically effective amount of a compound or composition comprising a malarial T- and B-peptide-bearing MAP, such an amount being effective to inhibit parasitemia in a mammalian host pursuant to infection by a malarial organism, preferably prior to exposure of the mammal to the malarial organism. Also contemplated are vaccines useful for inhibiting malarial infection by the sporozoite or other stages of malaria, comprising an effective amount of an immunogenic compound
comprising a malarial-origin T- and B-peptide-bearing MAP, and, optionally, a pharmaceutically acceptable carrier or diluent.
It will be apparent to those skilled in the art tha the products of this invention, once the concept is understoo can be prepared by procedures well known to the skilled artisan.
The Tarn procedures described in Proc. Natl. Acad. Sci. USA,
81:5409, 1988, Prosnett et al, _ _ Biol. Chem. , 26.3:1719, 1988; and Chenag et al, Proc. Natl. Acad. Sci. USA £56:4929, 1988, al of which are incorporated by reference are illustrative. A few general observations applicable to the synthesi of MAPS will be of assistance to those skilled in the art. Thes are:
1. The syntheses generally require a long coupling tim
(2-4 hours) . 2. Dimethyl formamide is generally a more suitable solven than methylene dichloride.
3. The peptide resin should not be dried at any stage o the synthesis since resolvation is extremely difficult.
4. Coupling should be closely monitored for completion o the coupling by the quantitative ninhydrin method.
5. The MAPS is best cleaved from the resin by the improve acid deprotection method with either HF or TFMSA (Tam, et al., J Am. Chem. Sic. , 105:6442, 1983; and J. Am. Chem. Soc. , 108:5242 1986) in dimethyl sulfide to avoid strong acid catalyzed sid reactions.
6. MAPS tend to strongly aggregate after cleavage from th resin support. Purification is best effected by extensiv dialysis under basic and strongly denaturing conditions in dialysis medium which is 8M in urea and mercaptoethanol to remov undesirable aromatic additives of the cleavage reactions such a p-cresol and thiocresol. Further purification, if desire, can b effected using high performance gel-permeation or ion exchang chromatography. In most cases the MAPS could be used directl without further purification. Table I summarizes the results of several tests con ducted to determine the efficacy of the products of this inven tion for eliciting an immunogenic response in mice. It will b
observed that the MAP based products of this invention have uniformly high antibody titers compared to irradiated sporozoite, recombinant CS protein or monomer BT peptide. It will be observed also that the response varies with the structure of the BT immunogens.
Table I. Comparison of antibody titers induced by different Immunogens of P. berghei and assayed with the recom¬ binant CS protein and sporozoites.
Antibody Response
Immunogen ' IFA titers RIA titers
Sporozoite rCS protein
sporozoitea 2,048 8 , 192 recombinant CS protein" 2,048 2 , 048 monomer BT peptidec 800 1 , 024
BT-MAP(4)C 128,000 408,000 TB-MAP(4 ) 32,000 400,000 BT-MAP(8) 24,000 100,000 TB-MAP(8) 64,000 400,000
a. Four mice of the H-2a halotype (B10,A strain) were injected intravenously two doses of 1x10s irradiated P. berghei sporozoites at two-week intervals. Sera were collected and pooled ten days after the last injection. Antibody titers expressed as the reciprocal of the highest positive serum solution were obtained by using glutaraldehyde-fixed P. berghei sporozoites in an indirect immunofluorescense assay (IFA) or the recombinant CS protein in a radioimmunoassay (RIA). b. Four mice of the H-2a halotype (A/J strain) were injected i.p. with 25 ug of the recombinant CS (rCVS) P. berghei protein, emulsified in CFA on day 0, and S.C. with 25 ug of the rCS protein in IFA on day 15. Sera were collected ten days later. c. Five mice of the H-2a halotype (A/J strain) were injected i.p. with each 50 micrograms of the peptide immunogens consisting of two occurrences of the repeating unit of P. berghei
CS protein immunodo inant region and one occurrence of a P. berghei CS protein-derived T-cell epitope peptide. The immuniza¬ tion schedule and the assay methods were similar to those for the recombinant CS protein. Upon challenge of the thus immunized mice with 2000 sporozoites each, the BT-MAP(4) produced complete protection (i.e., prevented parasitemia) in 80% of the mice; TB-MAP(4) protected 60% of the mice; BT-MAP(8) protected 50% of the mice; and TB-MAP(8) protected 60% of the mice. MAPs according to the present invention may be syn¬ thesized as follows:
Some of the following abbreviations are used in the synthetic examples, below:
Boc - t-butoxycarbonyl TFA - trifluoracetic acid
DMF - dimethylformamide
DCC - dicyclohexylcarbodiimide
Tos - tosyl
Bzl - benzyl Dnp - dinitrophenyl
2C1Z - 2-chlorocarbobenzoxy
DIEA - diisopropoylethylamine
TFMSA - trifluormethylsulfonic acid
BSA - bovine serum albumin HPLC - high performance liquid chromatography
TBR - tumor bearing rabbit
ATP - adenosine triphosphate
Dnp - dinitrophenyl.
C1Z - chlorobenzyloxycarbonyl BrZ - bromobenzyloxycarbonyl
ELISA - enzyme linked immunoabsorbent assay
Example 1 General Methods for the Synthesis of Multiple-Antigen Peptides The synthesis of an octabranched matrix core wit peptide antigen was carried out manually be a stepwise solid phase procedure [Merrifield, R.B. J. Am. Chem. Soc. (1963) 85
2149] on Boc-beta-Ala-0CH -Pam resin with a typical scale of 0.5 g of resin (0.05 mmol and a resin substitution level of 0.1 mmol/g for the present synthesis but was somewhat lower when a higher branching of core lysinlyl matrix was used). After the removal of the Boc-group by 50% TFA and neutralization of the resulting salt by DIEA, the synthesis of the first level of the carrier-core was achieved using 4 molar excess of preformed symmetrical anhydride of Boc-Lys (Boc) (0.2 mmol) in DMF and was then recoupled via DCC alone in CH C12. The second and third level were synthesized by the same protocol with 0.4 and 0.8 mmol respectively of preactivated Boc-Lys (Boc) to give the oc- tabranching Boc-Lys(Boc)-core matrix. However, all subsequent couplings of the peptide-antigen sequence require 1.6 mmol of preactivated amino acids. The protecting groups for the syn- thesis of the peptide antigens were as follows: Boc group for the alpha-amino terminus and benzyl alcohol derivatives for most side chains of trifunctional amino acids i.e., Arg(Tos), Asp(OBzl), Glu(OBzl), His(Dnp), Lys(2ClZ), Ser(Bzl), Thr(Bzl), and Tyr(BrZ). Because of the geometric increase in weight gain and volume, a new volume ratio of 30 ml of solvent per g of resin was used. Deprotection by TFA (20 min) was preceded by two TFA prewashes for 2 min each. Neutralization by DIEA was in CH C12 (5% DIEA) and there was an additional neutralization of DMF (2% DIEA). For all residues except Arg, Asn, Gin, and Gly, the first coupling was done with the preformed symmetric anhydride in CH2C1 and a second coupling was performed in DMF; each coupling was for 2 h. The coupling of Boc-Asn and Boc-Gly were mediated by the preformed 1-hydroxybenzotriazole ester in DMF. Boc-Gly and Boc-Arg were coupled with DCC alone to avoid the risk of formation of dipeptide and lactam formation, respectively. All couplings were monitored by a quantitative ninhydrin test [Sarin, V.K., et al Anal. Biochem. (1981) 117, 147] after each cycle, and if needed, a third coupling of symmetrical anhydride in DMF at 50" for 2 h was used [Tarn, J.P. (1985) In "Proc. Am. Pept. Sympo., 9th" (CM. Deber, K.D. Kopple and V.J.]. The synthesis was terminated with acetylation in acetic anhydride/DMF (3 mmol) containing 0.3 mmol of N,N-dimethylpyridine.
After completion of the MAPS, protected peptide-resin (0.3g) was treated with 1 M thiophenol in DMF for 8 h (3 times and at 50CC if necessary to complete the reaction) to remove the Nim-dinitrophenyl protecting group of His (when present), with 50% TFA/CH C12 (10 ml) for 5 min to remove the N -Boc group, and with the low/high-HF method [Tarn, J.P., Heath, W.F. & Merrifield, R.B. J. Am. Chem. Soc. (1983) 105, 6442] or the low-high TFMSA method [Tarn, J.P. Heath, W.F. & Merrifield, R.B. J. Am. Chem. Soc. (1986) lfl8, 5242] of cleavage to give the. crude MAPS. The crude peptide was then washed with cold ether mercaptoethanol (99:1, v/v, 30 ml) to remove p-thiocresol and p-cresol and extracted into 100 ml of 8 M urea, 0.2M dithiothreitol in 0.1 M Tris buffer, pH 8.0. To remove all the remaining aromatic byproducts generated in the cleavage step, the peptide in the dialysis tubing (Spectra Por 6,M.W. cutoff 1,000) was equi¬ librated in a deaerated and N2-purged solution containing 8 M urea, 0.1 M NH4HCO3-(NH4) C03, pH 8.0 with 0.1 M mercaptoethanol at 0°C for 24 n. The dialysis was then continued in 8M, and then in 2M urea, all in 0.1 M NH4HC03-(NH4)2C03 buffer, ph 8.0 for 12 h and then sequentially in H 0 and 1 M HOAc to remove all the urea. The lyophilized MAPS was then purified batchwise by high performance gel-permeation or ion-exchange chromatography. All of the purified material gave a satisfactory amino acid analysis.
Example 2
Synthesis and Purification of (Asn-Ala-Asn-ProJs-MAP (NP-16 MAP), a Peptide Derived from the Sporozoite Stage of Plasmodium falciparum.
The peptide, (Asn-Ala-Asn-Pro)s-Lys4-Lys -Lys-OH was synthesized by the general procedure described in Example 1.
The synthesis was initiated with Box-Lys(Boc)-0CH -Pam- resin (a copoly(styrene-l%-divinylbenzene resin) at a substitu¬ tion of 0.11 mmol/g of resin. The substitution was found to be 0.88 mmol/g after the sequential addition of three levels of Boc- Lys(Boc) to give an octabranching structure of [Boc-Lys(Boc) ] [Lys(Boc) -Lys(Boc)-OCH2~Pam resin. The synthesis continued with 2.5 g of resin in a modified Beckmann 990 synthesizer (Beckman
Instructions, Palo Alto, California). Synthesis was performed using a computer program that optimized all of the coupling steps. For example, the coupling of Boc-Ala and Boc-Pro were mediated by the symmetric anhydride method in a solvent ratio of CH2Cl2;dimethylformamide (1:3, v/v) to minimize aggregation and incomplete coupling. The coupling of Boc-Asn was by the per¬ formed 1-hydroxybenzotriazole active ester in the same solvent. Each amino acid underwent a double coupling protocol to maximize the coupling yield and essentially bring the reaction to >99.6% completion.
The protected peptide-resin was deprotected in por¬ tions. The initial deprotection was carried out with 1.57 g of dried peptide-resin in a reaction vessel and underwent the following procedure to remove the Boc-protecting group and other extraneous materials: CH2C12 (3 x 1 min wash); CF3C02H- CH2C12(1:1, 3 x 2 min) and CF3C02H (3 x 2 min wash) and then a cleavage reaction containing the following deprotecting reagents: trifluoromethanesulfonic aciditrif luoroacetic acid:tetrahydrothiophene: m-cresol (4:20:12:4, in ml) at 4°C for 3.5 h. The peptide released by the acidolytic cleavage of the sulfide-assisted cleavage procedure was collected and precipitated by ethyl ether (230 ml) prechilled to -30βC. The precipitate was centrifuged to a pellet and the ethyl ether was removed in vacuo. The peptide was then dissolved in 0.01M HOAc and dialyzed in 12 liters of 0.01M HOAc. The peptide was then lyophilized to dryness to obtain 60 mg of (Asn-Ala-Asn-Pro)gOMAP. Hydrolysis of the resulting resin after cleavage showed that about 90% of the peptide had been cleaved from the resin support. The low yield was due to incomplete precipitation of the peptide by the ether. The same peptide-resin (l.Og) was also cleaved by HF:anisole (9:1, v/v total 10ml) at 0βC for 1 h to give 220 mg of MAP after extensive extraction with 10 to 100% HOACc and a crude yield of 33%. The dialysis was carried out with 10% OHAc.
The peptide after dialysis was then analyzed first by amino -acid analysis (after hydrolysis by 6N HC1). The molar ratio of the MAP found was Asn:Ala;Pro;Lys: 1.97 (2): 1.03 (1):1 (1) :0.26(0.22) which was in agreement with those expected
theoretical values shown in parenthesis.
Example 3 General Methods for the Synthesis of Di-epitope Multiple Antigen Peptides Containing Malarial-Provenance T-cell and B-cell antigens.
(a) Method A. Linking Two epitopes in Tandem.
The synthesis of di-epitope MAPS was accomplished manually by a stepwise solid-phase procedure on Boc-Ala-OCH2-Pam resin (0.1 mmol of Ala is present in 1 g of resin) similar to those mono-epitope MAPS described in the previous examples. After the removal of the Boc group by 50% TFA and neutralization of the resulting salt by DIEA, the synthesis of the first level of the carrier core to form Boc-Lys(Boc)-Ala-OCH2-Pam resin was achieved using a 4 mole excess of Boc-Lys(Boc) via DCC alone in CH C12. The second and third level were synthesized by the same protocol, to give the octabranching Boc-Lys(Boc) core matrix. From this point onward, the synthesis of peptide antigens or two epitopes proceeded as those of the previous examples using the tertbutoxycarbonyl/benzyl protecting group strategy since they were arranged in tandem and were treated as if they are one antigen. Spacers such as tetra-peptide Gly-Pro-Pro-Gly are sometimes inserted between two peptide antigens to allow flexibility. After completion of the synthesis, the MAP-resin was treated with TFA to remove the N -Boc groups, then acetylated with 10% acetic anhydride/10% DIEA in Ch2Cl2, and finally cleaved with the low-high HF method to remove the MAP from the resin support. The crude peptide was then washed with cold ether/mer¬ captoethanol (99:1 vol/vol) to remove p-thiocresol and p-cresol, and extracted into 8 M urea in 0.1 M Tris.HCl buffer (pH 8.0). To remove the remaining aromatic by-products generated in the cleavage step, MAPs were dialyzed (Spectra Por 6, molecula weight cut off 1,000) in 8 M urea and then in 0.1 M acetic aci twice for 5-6 hours to remove the urea. The MAPs were lyophil ized from HQ three times to remove acetic acid.
(b) Method B. Linking Two or More Epitopes by Alternatin Branching of the Amino groups of Lysines
Because there are two amino groups in lysine and because these two amino groups could be protected selectively, the core matrix could be synthesized in such a way to produce that the N -NH group is protected with the acid-labile Boc group and the N -NE2 group is protected with the base-labile Fmoc (fluorenylmethoxycarbonyl) group, or vice versa, i.e. N -NH group is protected by the Fmoc group, and the N -NH group is protected by the Boc group. To achieve the synthesis of this core matrix using this selectivity, a core matrix containing N-~ NH2-Boc and N -NH2-Fmoc is illustrated. The synthesis of the core matrix was similar to those described in the previous examples using the Boc-Lys(Boc) for the branching for the first and second level. At the third level, Fmoc-Lys(Boc) was used for the Lys branching of the core to give for each Lys(Boc) and F oc- Lys end groups. The synthesis of the first epitope (or two epitopes in tandem) used the Boc/benzyl chemistry as described in the previous examples, but during this synthesis, neutralization time was reduced to 1 min to minimize the premature cleavage of the Fmoc group. The synthesis of the second epitope used the Fmoc/tertbutyl chemistry (i.e. the N -NH2 group is protected with Fmoc and the side chain is protected with tertbutyl alcohol derived protecting groups) and started after the completion of the first epitope using the Boc-aπ.ino acid chain was assembled. The F oc-amino acids were used with the side chain protecting groups for the trifunctional amino acids as follows: Glu(OBu'*-), AsptOBu1^), Lys(Boc) ThrfBu^, Ser(But), Tyr(But), Arg(P z), His(Trt), Trp(For), and Cys(But). Repetitive deprotection of N- Fmoc was by 20% piperidine in dimethylformamide and was preceded by one piperidine prewash and the coupling was mediated with DCC:HOBut in DMF. After completion of synthesis, the MAP resin was treated with low-high HF to remove the peptide chains from the resin. The workup and purification was essentially the same as those described in the previous examples. The procedure for assembling the peptide chain using the Fmoc.tertbutyl chemistry was as follows: (1) 20 mil DMF (3 1 min); (2) 20 ml piperidine/DMF (1:1 vol/vol()l min); (3) 20 ml piperidine/DMF (1:1 vol/vol) (10 min); (4) 20 ml DMF (3 x 1 min); (5) 20 ml
CH2C12(3 x 1 min); (6) 20 ml DMF (2 x 1 min); (7) amino acid (4 equiv) in DMF 5 ml (5 min), HOBt(4 equiv) in DMF, DCC(4 equiv) in
CH C1 were added for 2 h? (8) 20 ml DMF (4 x 2 min); (9) 20 ml
CH2C12(2 x 2 min). (c) Metnod C. Linking Two or More Epitopes via Disulfide Linkage of Two Preformed Heterologous MAPS.
To link two or more epitopes together via disulfide linkage of two preformed MAPS, a dipeptide such as Cys(Acm)-Ala is added at the carboxy terminus of the preformed MAPS as described in Example 3a or 3b. This could be achieved con¬ veniently before the start of the synthesis of the core matrix by adding Boc-Cys(Acm) to the Boc-Ala-OCH -Pam-resin. After the formation of the dipeptide 3oc-Cys(Acm)-Ala-0Ch_Pam-resin, the synthesis of the core matrix, the incorporation of one or more peptide antigen(s) using the procedures described above proceeded to give the preformed MAPS containing a Cys(Acm)-Ala dipeptide COOH-tail. The Cys(Acm) is stable to the HF deprotection method. The preformed MAPS containing the COOH Cys(Acm)-Ala dipeptide tail were purified. The dimerization of two heterologous preformed MAPs was achieved by oxidation with I2 to the disul¬ fide, and which also concomitantly remove the Acm-group from the cysteinyl residue. A detailed procedure was as follows. To 1 mmol of MAP, the heterologous preformed di-epitope MAPs contain¬ ing Cys(Acm) was dissolved in a de-aerated and N2-purified 50% acetic acid solution at room temperature, 50 ml of a solution of I2 in MeOH(l M solution) was added batchwise for 1 hour at 0°C. The reaction was quenched by adding 1 M aqueous sodium thiosul- fate (or ascorbic acid) until the yellow color was removed. MeOH was removed by dialysis in 0.1 acetic acid and the desired MAPs were purified by gel permeation chromatography, ion-exchange chromatography or reverse-phase high pressure liquid chromatog¬ raphy.
Claims (8)
- WHAT IS CLAIMED IS: 1. An antigenic product comprising a dendritic polymer having functional groups to which a plurality of both T- ' cell and B-cell epitopic peptide molecules selected from the group consisting of malarial B-cell and T-cell epitopic peptides are attached.
- 2. The product of claim 1 wherein at least one T- cell and B-cell epitopic peptide are attached in tandem to the same functional group. '
- 3. The product of claim 1 wherein said T-cell and B- cell epitopic peptides comprise T- and B-cell epitopic peptides derived from the circumsporozoite protein of at least one species of malaria selected from the group consisting of P. berghei, P. knowlesi, P. yoeli, P. malariae. P. ovale, P. falciparum, and P^. vivax.
- 4. The product of claim 3 wherein said B-cell epitopic peptides comprise amino acid sequences selected from the group consisting of (a) (NANP)χ (b) (DRAZGQFAG)χ wherein Z is independently selected from A or D; (c) (QAQGDGANAGQP)χ (d) (DPPPPNPN)χ (e) (YAAA(A)nGGG(G)mN)χ wherein Y is D or G indepen- dently; and n = 0 or 1; and m = 0 or 1 independently; (f) combinations of the foregoing; (g) peptides consisting of cyclic permutations of each of the repeating units (a) through (e);wherein x is an integer of at least 1; and the T-cell epitope is one or more T-cell epitopes derived from the CS protein of the same malarial species as the B-cell epitope.
- 5. The product of claim 4 wherein a T-cell epitopic peptide is appended directly to a functional group of the dendritic polymer and the B-cell epitopic peptide derived from the same malarial species is appended to the other end of the T- cell peptide, optionally via a linker.
- 6. The product of claim 4, wherein more than one T-cell epitopic peptide derived from the same malarial species is included along with at least one B-cell epitopic peptide derived from said species.
- 7. A vaccine against malaria comprising an immunogenically effective amount of the product of any one of claims 1-6.
- 8. A method for providing immunity against malaria in a mammal in need of such treatment comprising administering to said mammal an immunogenically effective amount of the product of anyone of claims 1-6.SUBSTITUTESHEET
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33685289A | 1989-04-12 | 1989-04-12 | |
US336852 | 1989-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5649290A true AU5649290A (en) | 1990-11-05 |
Family
ID=23317953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU56492/90A Abandoned AU5649290A (en) | 1989-04-12 | 1990-04-10 | Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0423315A4 (en) |
JP (1) | JPH03503539A (en) |
AU (1) | AU5649290A (en) |
CA (1) | CA2031197A1 (en) |
WO (1) | WO1990011778A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5560929A (en) * | 1986-08-18 | 1996-10-01 | The Dow Chemical Company | Structured copolymers and their use as absorbents, gels and carriers of metal ions |
US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
IT1241395B (en) * | 1990-04-02 | 1994-01-10 | Eniricerche Spa | IMMUNOGENIC COMPOUNDS, THE PROCEDURE FOR THEIR SYNTHESIS AND THEIR USE FOR THE PREPARATION OF ANIMALARY VACCINES |
GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
EP0911036A3 (en) * | 1992-02-11 | 2001-05-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
US5599912A (en) * | 1993-09-10 | 1997-02-04 | Coretech, Inc. | Compounds and methods for suppressing an immune response to sulfomethoxozale containing substances |
JPH08510761A (en) * | 1994-03-07 | 1996-11-12 | ザ・ダウ・ケミカル・カンパニー | Biologically active and / or targeted dendrimer complex |
US5591717A (en) * | 1994-04-06 | 1997-01-07 | Rojko; Jennifer L. | Branched apogenic peptide for inducing apoptosis |
GB2294690B (en) * | 1994-11-01 | 1998-10-28 | United Biomedical Inc | Peptides effective for diagnosis and detection of hepatitis C infection |
GB2308363A (en) * | 1995-12-22 | 1997-06-25 | Courtaulds Coatings | Dendritic Polymers |
WO1998030237A1 (en) * | 1996-12-24 | 1998-07-16 | New York University | Polyoxime-based anti-malarial vaccines |
EA002545B1 (en) * | 1997-01-21 | 2002-06-27 | Нью Йорк Юниверсити | Universal t-cell epitopes for anti-malarial vaccines |
FR2772770B1 (en) * | 1997-12-19 | 2000-01-28 | Oreal | NOVEL COMPOUNDS SELECTED AMONG HYPERBRANCHED POLYMERS AND DENDRIMERS HAVING A PARTICULAR GROUPING, METHOD OF PREPARATION, USE AND COMPOSITIONS COMPRISING THE SAME |
ITRM20010563A1 (en) * | 2001-09-14 | 2003-03-14 | Univ Siena | MULTIPLE ANTIGEN PEPTIDES AS ANTIDOTES IN SNAKE POISON POISONING. |
PT1940916T (en) | 2005-10-25 | 2017-03-20 | Starpharma Pty Ltd | Macromolecular compounds having controlled stoichiometry |
WO2017058114A1 (en) * | 2015-10-01 | 2017-04-06 | Nanyang Technological University | Butelase-mediated peptide ligation |
US11627738B2 (en) | 2016-01-06 | 2023-04-18 | University Of Florida Research Foundation, Inc. | Stimuli-responsive polymeric nanoparticles, methods of making stimuli-responsive polymeric nanoparticles, and methods of using stimuli-responsive polymeric nanoparticles |
WO2018017954A1 (en) * | 2016-07-21 | 2018-01-25 | Rutgers, The State University Of New Jersey | Antimicrobial cationic systems and methods of use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4289872A (en) * | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
GB2154240A (en) * | 1984-01-27 | 1985-09-04 | Univ New York | Immunodominant epitope of the circumsporozoite surface protein |
US4707357A (en) * | 1984-06-26 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Immunologically active peptides capable of inducing immunization against malaria and genes encoding therefor |
EP0229829B1 (en) * | 1985-07-12 | 1995-02-22 | New York University | Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein |
US4713366A (en) * | 1985-12-04 | 1987-12-15 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
US4957738A (en) * | 1987-01-14 | 1990-09-18 | Patarroyo Manuel E | Protein copolymer malaria vaccine |
GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
-
1990
- 1990-04-10 AU AU56492/90A patent/AU5649290A/en not_active Abandoned
- 1990-04-10 WO PCT/US1990/002039 patent/WO1990011778A1/en not_active Application Discontinuation
- 1990-04-10 JP JP2507483A patent/JPH03503539A/en active Pending
- 1990-04-10 EP EP19900907743 patent/EP0423315A4/en not_active Withdrawn
- 1990-04-10 CA CA002031197A patent/CA2031197A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH03503539A (en) | 1991-08-08 |
EP0423315A4 (en) | 1991-11-13 |
CA2031197A1 (en) | 1990-10-13 |
WO1990011778A1 (en) | 1990-10-18 |
EP0423315A1 (en) | 1991-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5229490A (en) | Multiple antigen peptide system | |
AU5649290A (en) | Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccine | |
Yi-An et al. | Chemically unambiguous peptide immunogen: preparation, orientation and antigenicity of purified peptide conjugated to the multiple antigen peptide system | |
AU667578B2 (en) | Retro-, inverso-, and retro-inverso synthetic peptide analogues | |
EP1336617B1 (en) | Conotoxins | |
AU2007327829B2 (en) | Coiled-coil lipopeptide helical bundles and synthetic virus-like particles | |
EP0229829B1 (en) | Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein | |
US5019383A (en) | Fatty acid carriers for synthetic peptides | |
US6074650A (en) | Membrane anchor/active compound conjugate, its preparation and its uses | |
US6024964A (en) | Membrane anchor/active compound conjugate, its preparation and its uses | |
CN1054772A (en) | Synthetic polypeptide | |
De Oliveira et al. | Synthetic approaches to multivalent lipopeptide dendrimers containing cyclic disulfide epitopes of foot-and-mouth disease virus | |
CA1339590C (en) | Peptide mixture useful for the malaria vaccine manufactrue, process for the preparation of said mixture and use thereof | |
EP0450715B1 (en) | Immunogenic compounds, the process for their synthesis and their use in the preparation of antimalaria vaccines | |
WO1993003766A1 (en) | Multiple antigen peptides for use as hiv vaccines | |
PH26239A (en) | HIV related peptide immunogenic antigens and use thereof as subunit vaccine for AIDS virus | |
Corradin et al. | Malaria vaccine development using synthetic peptides as a technical platform | |
US5095093A (en) | Protective four amino acid epitope against Plasmodium vivax malaria | |
JPH07505878A (en) | Synthetic polypeptide derived from HIV envelope glycoprotein | |
EP0093851A2 (en) | Fatty acid carriers for synthetic vaccines | |
JP4568842B2 (en) | Method for producing partial peptide of Enolase protein of Plasmodium falciparum | |
Londono et al. | Secondary structure and immunogenicity of hybrid synthetic peptides derived from two Plasmodium falciparum pre-erythrocytic antigens. | |
US5118501A (en) | Polypeptidic composition useful for the preparation of antimalarial vaccines and of diagnostic kits for the detection of antimerozoite antibodies | |
EP0398443B1 (en) | Immunogenic compounds and their use in the preparation of genetically unrestricted synthetic vaccines and in the immunoenzymatic determination of antisporozoite antibodies of plasmodium malariae | |
NL8701686A (en) | POLYPEPTIDE SUITABLE FOR THE PREPARATION OF ANTIMALARIA VACCINES AND FOR DIAGNOSTIC COMPOSITIONS FOR THE INDICATION OF MALARIA DISORDERS. |